“We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib, providing further evidence that these two agents have independent mechanisms of resistance.

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their ...

4 In patients who had been previously exposed to chemotherapy and trastuzumab, treatment with lapatinib increased the response rate from 13.9% to 23.7% when used in combination with capecitabine.

Trastuzumab appears to improve outcomes in patients with BM secondary to controlling extra-CNS disease, which remains the main cause of cancer-related mortality. The single-agent lapatinib has a ...

compared T-DM1 with the standard combination of capecitabine and lapatinib [Tykerb, Novartis] in patients with metastatic, HER2-positive breast cancer previously treated with trastuzumab ...

A total of 104 patients were enrolled, of whom 53 received DV and 50 received Lapatinib plus Capecitabine. All patients had previously been treated with Trastuzumab and Taxanes. As of data cutoff date ...